Business Context and Reporting Period
Company: Graham Corporation (NYSE: GHM)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year ended March 31, 2025 (Fiscal 2025)
Business Overview: A global leader in mission-critical fluid, power, heat transfer, and vacuum technologies serving the Defense, Energy & Process, and Space industries. The company operates through its headquarters in Batavia, NY, and subsidiaries including Barber-Nichols (Arvada, CO) and P3 Technologies (Jupiter, FL, acquired Nov 2023).
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Net Sales | $209.9 million | $185.5 million | +13% |
| Gross Profit | $52.9 million | $40.6 million | +30% |
| Gross Margin | 25.2% | 21.9% | +330 bps |
| Net Income | $12.2 million | $4.6 million | +168% |
| Diluted EPS | $1.11 | $0.42 | +164% |
| Adjusted EBITDA | $22.4 million | $13.3 million | +69% |
| Operating Cash Flow | $24.3 million | $28.1 million | -14% |
| Cash & Equivalents | $21.6 million | $16.9 million | +28% |
| Backlog | $412.3 million | $390.9 million | +5% |
| Debt | $0 (Revolving Credit Facility) | $0 | - |
Note: All dollar amounts in thousands except per share data. Adjusted EBITDA is a non-GAAP measure.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by a $22.4 million increase in Defense sales (23% growth) due to program growth and improved pricing. Space sales increased 11% largely due to the P3 acquisition. Energy & Process sales remained flat.
- Margin Expansion: Gross margin improved by 330 basis points due to fixed overhead leverage, better execution, and a $1.3 million grant from the BlueForge Alliance for welder training.
- Profitability: Net income more than doubled, aided by a $1.2 million gain from the revaluation of the P3 contingent earn-out liability and lower interest expense.
- Orders: Total orders decreased 14% to $231.1 million, primarily due to a record backlog of Defense orders in Fiscal 2024. However, the book-to-bill ratio was 1.1x.
- Capital Expenditures: Increased significantly to $19.0 million (from $9.2 million) to fund a new 30,000 sq. ft. manufacturing facility in Batavia and a cryogenic testing facility in Florida.
Guidance, Outlook, and Risks
Fiscal 2026 Outlook
- Net Sales: $225.0 million to $235.0 million.
- Gross Profit Margin: 24.5% to 25.5% (includes estimated $2.0M-$5.0M tariff impact).
- SG&A Expenses: 17.5% to 18.5% of sales.
- Adjusted EBITDA: $22.0 million to $28.0 million.
- Capital Expenditures: $15.0 million to $18.0 million.
Management Commentary
Management expects to achieve long-term goals of 8-10% annualized organic revenue growth and low-to-mid-teen Adjusted EBITDA margins by Fiscal 2027. A planned management transition occurred in June 2025, with Matt Malone succeeding Daniel J. Thoren as CEO.
Risks and Contingencies
- Customer Concentration: Defense sales accounted for 58% of revenue; two customers each represented over 10% of revenue. 83% of backlog is Defense-related, creating exposure to U.S. Navy funding disruptions.
- Regulatory & Compliance: The company self-reported a potential ITAR violation regarding unauthorized export of technical data. An investigation into misconduct at the India subsidiary (GIPL) concluded in Fiscal 2024; employees were terminated and authorities notified.
- Macroeconomic: Risks include inflation, supply chain disruptions, and potential tariff increases estimated to impact Fiscal 2026 by $2.0M-$5.0M.
- Legal: Ongoing asbestos-related litigation, though management does not expect a material adverse effect.
Investor Verification Checklist
- Defense Funding Stability: Verify the status of U.S. Navy appropriations and potential impacts on the 83% Defense backlog.
- Margin Sustainability: Assess the impact of the one-time $1.3M BlueForge grant and the $1.2M earn-out gain on future profitability.
- Tariff Exposure: Monitor the realization of the $2.0M-$5.0M tariff cost estimate included in Fiscal 2026 guidance.
- Compliance Status: Track the resolution of the self-reported ITAR violation and the GIPL investigation.
- Capital Deployment: Confirm the timeline and funding sources for the Batavia expansion and Florida testing facility.